Innate Pharma Releases Total Number of Shares and Voting Rights

Innate Pharma, a global biotechnology company specializing in immunotherapies for cancer patients, has announced the total number of shares outstanding and voting rights as of October 3, 2023. The company’s commitment to transparency and compliance with regulatory requirements is evident in this release.

According to the disclosure, Innate Pharma has a total of 80,645,333 ordinary shares outstanding. Additionally, there are 6,509 Preferred Shares 2016 and 7,581 Preferred Shares 2017. The total number of theoretical voting rights is reported as 81,402,523, while the total number of exercisable voting rights stands at 81,383,948.

These figures are crucial for calculating shareholding thresholds and ensuring accurate representation of the company’s ownership structure. Innate Pharma adheres to the recommendations set forth by the Autorité des Marchés Financiers (AMF), the French stock-market authorities, to provide comprehensive information to the market.

Innate Pharma’s innovative approach focuses on leveraging the innate immune system through therapeutic antibodies and its proprietary ANKET® platform (Antibody-based NK cell Engager Therapeutics). The company’s portfolio includes promising programs such as lacutamab, developed for advanced cutaneous T cell lymphomas and peripheral T cell lymphomas, and monalizumab, a collaboration with AstraZeneca targeting non-small cell lung cancer. Additionally, Innate Pharma is actively developing ANKET® multi-specific NK cell engagers to address various tumor types.

As a trusted partner to biopharmaceutical companies like Sanofi and AstraZeneca, as well as leading research institutions, Innate Pharma is dedicated to accelerating innovation and research for the benefit of cancer patients. With headquarters in Marseille, France, and a US office in Rockville, MD, the company is listed on Euronext Paris and Nasdaq.

For more information about Innate Pharma and its groundbreaking immunotherapies, visit their website at Stay updated on their latest developments by following them on Twitter and LinkedIn.

Please note that this press release contains forward-looking statements, and actual results may differ from those anticipated due to various risk factors. Interested parties are encouraged to refer to the full disclaimer provided by Innate Pharma for a comprehensive understanding of these risks.

Source: Business Wire

Leave a comment